Efficacy Of The Treatment Of The Ocular Surface Desease With Autologous Serum Due To The Use Of Hypotension Agents In Patients With Glaucoma

To analyze the effectiveness of treatment with 50% autologous serum in ocular surface disease caused by ocular hypotensive medications in the cornea and refractive surgery service of the General Hospital of Mexico in 2023.

Quantitative, observational, analytical, retrospective.

Quantitative, observational, analytical, retrospective.

TBUT, at baseline 76.3%, then it decreases to 26.3% in the first month, to reach 2.5% in the third month, percentage changes are observed, at baseline 100%, then it decreases in the first month to 61.3%, and in the third month 50%. changes in conjunctival epithelial erosions, at baseline 75%, then in the first month 52.5%, reaching 51.3% in the third month. Variations are observed in the symptom scores, at baseline it is equal to 10.54 points, in the first month 8.64 points, and finally in the third month 7.75 points, significance and variations are observed in the limitations scores, at baseline it is equal to 6.31 points, in the first month 5.58 points, and finally in the third month 5.24 points, being statistically significant (p<0.05).

The effectiveness of treatment with autologous serum was demonstrated in reducing the time in the rupture of corneal epithelial erosions with fluorescein and conjunctival epithelial erosions, favorable changes were developed in the decrease in average scores of global results of the OSDI questionnaire at three months in ocular surface disease caused by ocular hypotensive medications, which will be treated with 50% autologous serum.